Syndax reported third-quarter Revuforj net revenue of $60.7 million, up 90%, and Niktimvo net revenue of $67.4 million, up 47%. MAXPIRe missed its primary endpoint in IPF, and Syndax does not plan to move forward with further axatilimab development there.
SNDX · Syndax Pharmaceuticals Inc · Documents
$8.72
-0.41 (-4.49%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$778.67M
Shares
89.30M
Volume · Nov 20
2.18M
Avg daily vol (3M)
2.61M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2026
Nov 2
Quarterly report
10-Q
FY2026 Q3, ended Sep 30
Revuforj revenue rose 90%; MAXPIRe missed primary endpoint
Revenue $83.3M
▲ 81.6%
Net loss $49.43M
Diluted EPS -$0.55
Nov 2
Current report
8-K
New CFO appointment effective November 9, 2026
Syndax Pharmaceuticals appointed Aaron A. Ondrey CFO effective November 9, 2026, succeeding retiring Keith A. Goldan. Ondrey receives a $543,000 annual salary, 45% target bonus and option for 270,000 shares.
Aug 4
Aug 4
Aug 4
Quarterly report
10-Q
FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2
AI summary on its way
Revenue $72.79M
▲ 91.8%
Net loss $49.36M
Diluted EPS -$0.55
Jul 14
Jun 10
Current report
8-K
Director or officer change, or executive pay, Shareholder vote results
AI summary on its way
Jun 10
Current report
8-K
Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity
AI summary on its way
Jun 4
Jun 4
Current report
8-K
Events of Jun 3
Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity, Other events
AI summary on its way
Apr 30
Apr 30
Apr 30
Apr 30
Apr 30
Quarterly report
10-Q
FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1
AI summary on its way
Revenue $64.86M
▲ 223.6%
Net loss $42.67M
Diluted EPS -$0.48
Feb 26
Feb 26
Feb 26
Annual report
10-K
FY2025, ended Dec 31
Annual report for FY2025
AI summary on its way
Revenue $172.35M
▲ 627.8%
Net loss $285.42M
Diluted EPS -$3.29
Jan 12
2025
Dec 19
Current report
8-K
Events of Dec 18
Charter or bylaw amendment, or fiscal year change
Nov 3
Earnings call
Q3 2025 earnings call
Nov 3
Current report
8-K
Financial results
Nov 3
Quarterly report
10-Q
FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $45.87M
▲ 267.0%
Net loss $60.72M
Diluted EPS -$0.70
Oct 24
Current report
8-K
Other events
Aug 4
Earnings call
Q2 2025 earnings call
Aug 4
Current report
8-K
Financial results
Aug 4
Quarterly report
10-Q
FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $37.96M
▲ 984.5%
Net loss $71.85M
Diluted EPS -$0.83
Jun 26
Current report
8-K
Events of Jun 24
Director or officer change, or executive pay
May 16
Current report
8-K
Events of May 12
Director or officer change, or executive pay, Regulation FD disclosure
May 5
Earnings call
Q1 2025 earnings call
May 5
Current report
8-K
Financial results, Other events
May 5
Quarterly report
10-Q
FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $20.04M
Net loss $84.85M
Diluted EPS -$0.98
Apr 1
Proxy statement
DEF 14A
Proxy statement
Apr 1
Annual report to holders
ARS
Annual report to holders
Apr 1
Proxy statement
DEFA14A
Proxy statement
Mar 3
Earnings call
Q4 2024 earnings call
Mar 3
Current report
8-K
Financial results, Other events
Mar 3
Annual report
10-K
FY2024, ended Dec 31
Annual report for FY2024
Revenue $23.68M
Net loss $318.76M
Diluted EPS -$3.72
2024
Dec 20
Current report
8-K
Director or officer change, or executive pay
Nov 18
Current report
8-K
Events of Nov 15
Other events
Nov 12
Current report
8-K
Other events
Nov 5
Earnings call
Q3 2024 earnings call
Nov 5
Current report
8-K
Financial results
Nov 5
Quarterly report
10-Q
FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Revenue $12.5M
Net loss $84.13M
Diluted EPS -$0.98
Nov 4
Current report
8-K
Entered into a material agreement
Aug 1
Earnings call
Q2 2024 earnings call
Aug 1
Current report
8-K
Financial results
Aug 1
Quarterly report
10-Q
FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Revenue $3.5M
Net loss $68.06M
Diluted EPS -$0.80
May 15
Current report
8-K
Events of May 14
Director or officer change, or executive pay, Shareholder vote results, Regulation FD disclosure
May 8
Earnings call
Q1 2024 earnings call
Showing 1–50 of 154 documents
Key facts
CIK
1395937
CUSIP
87164F105
13F (30d)
241 filings
222 filers
Visit website
Investor relations